Premium
Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit
Author(s) -
Thomas Michelle L,
Hewett Peter J,
Ruszkiewicz Andrew R,
Moore James WE
Publication year - 2015
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12411
Subject(s) - microsatellite instability , medicine , colorectal cancer , oncology , pathological , hazard ratio , chemotherapy , stage (stratigraphy) , proportional hazards model , adjuvant chemotherapy , adjuvant therapy , cancer , adjuvant , multivariate analysis , cohort , dna mismatch repair , microsatellite , breast cancer , allele , biology , confidence interval , paleontology , biochemistry , gene
Aim In colorectal cancer ( CRC ), adjuvant therapy is offered on the basis of stage and attempts to identify factors to better target treatment have not been successful. Recent work suggested that mismatch repair deficient CRCs may not benefit from 5 FU adjuvant chemotherapy but studies remain conflicting. We aimed to determine if gender, tumor site, tumor pathological characteristics and microsatellite instability ( MSI ) predict survival benefit from adjuvant chemotherapy in stage C CRC . Methods Data were collated on ACPS (Australian Clinico‐pathological Staging System) stage C CRC cases that underwent curative resection over a 23‐year period. Pathology was reevaluated, DNA was extracted from the formalin‐fixed paraffin specimen, and MSI status was established by BAT 26 instability. Multivariate analysis was performed using Cox proportional hazard model and effects modification interaction testing. Results In total 814 unselected cases were included, of whom 37% received chemotherapy. Seventy‐seven cases exhibited MSI. Overall, adjuvant chemotherapy produced a cancer‐specific survival benefit ( HR 0.52, 95% CI 0.39–0.70; P < 0.0001). On interaction testing, none of the examined parameters significantly influenced the magnitude of that survival benefit. Chemotherapy was beneficial in both the MSI ( HR 0.08, 95% CI 0.02–0.27; P = < 0.0001) and the microsatellite stable cohort ( HR 0.62, 95% CI 0.47–0.81; P = 0.001). Conclusion These results suggest that survival benefit from 5FU adjuvant chemotherapy for stage C CRC does not vary according to gender, site of tumor, pathological characteristics or MSI status. This study suggests that it would be unwise to exclude patients from being offered adjuvant chemotherapy on the basis of MSI.